A round burgundy crest emblem with simple gold ring detailing, plain and formal in style
A wide horizontal photograph of mountain scenery near Banff with pale turquoise sky, dark evergreen slopes, and a soft muted mood
A round burgundy crest emblem mirroring the first, with plain gold ring detailing and a formal quiet mood

Annual Scientific Meeting of the Canadian Organization of Medical Physicists — July 9–12, 2014, The Banff Centre, Banff, Alberta, Canada

Navigating Radiotherapy Device Approval Across Canada and Australia

Regulatory frameworks for medical devices vary considerably across jurisdictions, even between countries that share many clinical practices. For radiation oncologists, medical physicists, and biomedical engineers, the rules governing linear accelerators, brachytherapy afterloaders, treatment couches, and quality assurance instrumentation shape procurement cycles, installation timelines, and post-market obligations. A device approved in one nation may still require a separate submission, conformity assessment, or licence amendment before it is installed at a clinic in another.

Australian practitioners encounter the Canadian system when evaluating equipment for cross-border trials, reviewing vendor pitches aimed at multiple regulators, or interpreting commissioning data from Canadian centres. Understanding how Health Canada classifies and licences a radiotherapy system helps teams benchmark those decisions against what the Therapeutic Goods Administration, ARPANSA, and state regulators require locally. The aim here is to map the Canadian pathway clearly and connect it with everyday realities for teams in Sydney, Melbourne, Brisbane, and smaller regional centres.

Why Cross-Border Regulatory Knowledge Matters

Radiotherapy hardware does not respect borders. A cobalt-to-linac replacement in Vancouver, a stereotactic radiosurgery upgrade in Sydney, and a brachytherapy expansion in regional Queensland may involve the same vendor, the same shipping crate, and the same software build. Each site, however, sits within a distinct regulatory environment that determines how a device is approved, which performance standards are mandatory, and how adverse events are reported. Clinicians who grasp these parallel systems ask sharper procurement questions and avoid installation surprises.

Australia and Canada are particularly useful comparisons because both operate federal regulators with similar scopes (Health Canada and the TGA), maintain provincial or state overlays, and rely on consensus standards such as IEC 60601 and IEC 62083. Both emphasise lifecycle oversight rather than one-off pre-market approval, which means post-market surveillance, licence amendments, and quality system audits are integral. Recognising that structural symmetry helps translate lessons learned in one system into practical advice for the other.

Health Canada and the Device Authorisation Pathway

Health Canada, working through the Therapeutic Products Directorate and the Medical Devices Bureau, administers the Medical Devices Regulations under the Food and Drugs Act. Manufacturers seeking to place a radiotherapy device on the Canadian market generally pursue a Medical Device Licence (MDL) for Class II, III, and IV devices, with deeper review and clinical evidence expectations for higher-risk classes. An Investigational Testing Authorization (ITA) is the alternative route used for clinical investigations before full market availability, such as novel motion-management platforms or prototype surface-guided systems.

Once an MDL is granted, the device appears on the publicly searchable Medical Device Active Licence Listing (MDALL), which Australian procurement teams frequently consult when reviewing the regulatory pedigree of an offering. Recent policy directions have emphasised real-world evidence and lifecycle vigilance, bringing Canadian practice closer to the model used by Australia's TGA. The MDL number also supports cross-referencing with provincial health authorities that may impose additional facility-level requirements before clinical use.

Device Classification and Conformity Assessment

Class assignment drives the documentation burden. In Canada, most linear accelerators, HDR afterloaders, and treatment planning systems sit in higher-risk bands because they directly influence patient exposure to ionising radiation. Manufacturers demonstrate conformity through a recognised pathway, often referencing ISO 13485 for quality management and ISO 14971 for risk management, supported by design verification, software validation, and usability engineering records. Class IV devices attract the deepest review, which can include site inspections and detailed clinical data.

Clinical evidence expectations have evolved meaningfully. Health Canada now routinely expects reports aligned with the IMDRF Summary Technical Documentation format, including a clinical evaluation report that compares the device to the state of the art and identifies residual risks. This mirrors what the TGA asks for under the Australian regulatory framework for medical devices, where inclusion on the Australian Register of Therapeutic Goods (ARTG) requires comparable evidence packages. Vendors active in both markets often maintain a single technical file with jurisdiction-specific annexes, reducing duplication while satisfying each reviewer.

The Canadian Nuclear Safety Commission Layer

Health Canada is not the only regulator in the picture. Radiotherapy devices containing sealed radioactive sources, producing ionising radiation, or interfacing with nuclear medicine workflows fall under the Canadian Nuclear Safety Commission (CNSC), which administers the Nuclear Safety and Control Act. Linacs, HDR afterloaders, and some kilovoltage units may trigger CNSC licensing independent of the MDL process. The CNSC evaluates shielding calculations, source security, worker dose records, and emergency planning, and it conducts announced facility inspections.

Australian readers will recognise the equivalent role played by ARPANSA. In New South Wales, the Environment Protection Authority oversees radiation safety licensing; in Victoria, the Department of Health performs a similar function; in Queensland, the Radiation Health Unit administers the Radiation Safety Act 1999. Federal safety guidance, state-level facility licensing, and a parallel health technology pathway for the device itself is the principle in both countries. Knowing which body controls which aspect is the first step in avoiding stalled installations.

Australian Parallels: TGA, ARPANSA, and State Regimes

The Therapeutic Goods Administration evaluates radiotherapy devices under the Australian regulatory framework, with ARTG inclusion typically requiring conformity assessment certificates from the TGA or from European Notified Bodies during the current transition. Australian sponsors maintain compliance evidence, report adverse events through the IRIS system, and manage recalls where necessary. At major centres such as Peter MacCallum in Melbourne, the Royal Prince Alfred in Sydney, or the Princess Alexandra in Brisbane, sponsor duties are often handled by clinical engineering or radiation oncology physics departments that interface directly with manufacturers.

A typical Friday morning in a Sydney radiotherapy department might combine linac morning QA, a planning system upgrade validation, and a phone call with the state regulator about an installation timeline. Smaller regional centres, from Cairns to Launceston, face additional hurdles because they often lack on-site regulatory affairs staff, relying on remote vendor support and ARPANSA guidance to keep projects on track. Understanding which approvals must be in place before commissioning, and which can follow installation, helps these teams set realistic go-live dates.

Practical Impact on Radiotherapy Programs Down Under

The practical differences between the Canadian and Australian systems most often surface during multi-site trials, vendor demonstrations, and decommissioning projects. A device approved in Canada but not yet on the ARTG cannot simply be shipped to an Australian hospital for a sponsored evaluation; an ITA-equivalent application or a special access scheme request may be needed. Even with both MDL and ARTG listing, provincial or state amendments to existing radiation licences can extend timelines by several months.

Procurement teams benefit from a compact regulatory dossier alongside the commercial evaluation. Asking vendors for the MDL number, the ARTG inclusion number, the CNSC licence class, and the corresponding state radiation licence category creates a single page that supports capital committee approvals, reimbursement submissions, and clinical governance sign-off. Adding this requirement to the request for proposal template encourages vendors to standardise evidence packages, easing the administrative load on busy physics departments.

Delegates at the student-night gathering during the 2014 COMP Annual Scientific Meeting in Banff often found that conversations about cross-border regulation began with shared commissioning data and ended with shared questions about what happens when a device moves between jurisdictions. The same theme recurs among Australian and Canadian trainees who later move into hospital leadership. Building regulatory literacy early pays dividends throughout a career in medical physics.

Working Checklist for Clinicians, Manufacturers, and Procurement Teams

Before committing to a new radiotherapy device or expanding an existing service, the following practical steps help align Canadian approval evidence with Australian expectations:

  • Confirm the MDL number on Health Canada's MDALL database and the ARTG entry on the TGA database, recording both in the procurement file.
  • Identify whether the CNSC has issued a separate licence class for the device, then map that to the relevant ARPANSA code and the state radiation safety licence category.
  • Request a single technical file summary from the vendor covering ISO 13485 certification, IMDRF-format clinical evaluation, and ISO 14971 risk management documentation.
  • Plan state-level licence amendments in parallel with installation, since radiation safety approvals often drive go-live dates more than the ARTG listing itself.
  • Establish post-market surveillance workflows covering adverse event reporting through IRIS in Australia and the corresponding Canadian channels, with clear internal escalation paths.
  • For multi-jurisdictional clinical trials, confirm whether an ITA-equivalent application is needed in Australia and align ethics submissions with each site's research governance office.

Reviewing the Canadian regulatory landscape offers more than academic interest for Australian radiotherapy professionals. It provides a structured way to benchmark local processes, anticipate procurement friction, and design installation timelines that respect multi-layered approval. Teams that invest in regulatory literacy tend to commission devices more smoothly, manage post-market obligations with confidence, and engage vendors from a position of informed authority. Readers with questions about how the 2014 COMP programme addressed these topics can reach the organising committee through the contact-us page.